Kraig Biocraft Highlights Commercial Scaling And Future Potential Of Spider Silk
Kraig Biocraft Laboratories Founder and CEO Kim Thompson has outlined the company’s progress in scaling recombinant spider silk production, focusing on commercial readiness, technological advantages and long-term industry applications.
The company is advancing its proprietary platform using genetically engineered silkworms to produce recombinant spider silk fibres, leveraging existing global silk manufacturing infrastructure rather than building a new production ecosystem. This approach is aimed at enabling faster scaling and smoother integration into established textile supply chains.
Thompson noted that this model provides a key competitive advantage by combining natural biological spinning processes with industrial-scale silk production systems, supporting consistent fibre quality and the potential for metric-tonne-level output.
The discussion also highlighted recent technological milestones, including advances in genetic engineering, expansion of intellectual property and successful development of high-performance spider silk variants inspired by species such as the Darwin Bark Spider.
Operational progress, including expansion into Southeast Asia and the use of production systems such as BAM-1 and BAM-1 Alpha, has strengthened the company’s commercial manufacturing capabilities.
Thompson emphasized that recombinant spider silk offers a unique combination of strength, elasticity and sustainability, making it suitable for applications in premium apparel, performance textiles, technical fabrics, luxury fashion, composites and defence sectors.
Looking ahead, the company remains focused on achieving reliable, scalable and sustained commercial production while expanding adoption across global textile value chains.
